Subcutaneous Sarclisa scores Phase III win

Sanofi (Euronext: SAN) has announced promising results from its Phase III IRAKLIA study, which tested a subcutaneous version of Sarclisa (isatuximab) in combination with chemo, in multiple myeloma.

The regimen, which includes pomalidomide and dexamethasone, is being developed for people with relapsed or refractory disease. The study demonstrated that the SC formulation met its co-primary endpoints, showing non-inferiority compared to the intravenous version.

The IRAKLIA trial is the first global Phase III study to evaluate a cancer treatment delivered via an on-body delivery system. The device, developed by Enable Injections, allows high-volume SC administration and aims to improve patient convenience by reducing the time spent in healthcare settings.